Mr. Ligner said, "I have long admired Avantor as an industry leader with an attractive portfolio, global supply chain and diverse customer base. I believe this company has tremendous potential and I look forward to working closely with our Board, leadership team and the thousands of talented associates around the world to capitalize on market opportunities and create value for shareholders."

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it has named Emmanuel Ligner, President and Chief Executive Officer, effective August 18, 2025.

Mr. Ligner succeeds Michael Stubblefield, who will, as previously announced, step down from his role as Director, President and Chief Executive Officer upon Mr. Ligner's appointment.

Mr. Ligner brings more than 30 years of experience and an outstanding track record of driving growth and value creation in the life sciences industry. During his 12 years at GE Life Sciences, Mr. Ligner held several global leadership positions with a focus on commercial growth, culminating in his appointment as President and CEO. Following the sale of the biopharma business at GE Life Sciences to Danaher Corporation, Mr. Ligner led the launch of Cytiva and spent four years building the business into a powerful standalone life sciences brand including the integration of Pall Life Sciences. He most recently served as Chief Executive Officer of Cerba HealthCare.

"Emmanuel is a proven CEO and leader with extensive experience driving commercial growth and building high-performing, empowered teams at large-scale global life sciences organizations," said Jonathan Peacock, Chairman of the Board of Directors. "The Board is confident Emmanuel is the right person to lead Avantor in its next chapter to deliver competitive growth and value in both Lab Solutions and Bioscience Production."